# Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

> **NCT07371585** · PHASE2 · RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DEVICE:** Digital Health Tools
- **DRUG:** T-DXd
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT07371585
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-18
- **Primary completion:** 2029-08-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371585, "Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07371585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*